Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02179)

VOLUNTARY ANNOUNCEMENT

RECEIPT OF PHASE III CLINICAL TRIAL SUMMARY REPORT FOR NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis. References are made to the Company's voluntary announcements dated July 26, 2023, December 29, 2023, October 23, 2024 and January 2, 2025 in relation to the approval of the phase I and phase III clinical trials, the initiation of phase III clinical trial, and the completion of subject enrollment for the Phase III clinical trial of the Company's novel adjuvanted recombinant shingles vaccine REC610 ("**REC610**") in China.

The board of directors of the Company (the "**Board**") is pleased to announce that the Phase III clinical trial (the "**Study**") of the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Group has been completed (registration number: CTR20243742), and the Company has recently obtained the clinical trial summary report (the "**Summary Report**") of the Study.

REC610 is a novel adjuvanted recombinant shingles vaccine independently developed by the Company, which utilizes the glycoprotein E (gE) protein of the varicella-zoster virus (VZV) as its antigen and is formulated with BFA01, a novel adjuvant independently developed by the Company. BFA01 can promote the production of high levels of gE-specific CD4+ T cells and antibodies. REC610 is indicated for the prevention of herpes zoster in adults aged 40 and above. If REC610 is ultimately approved for marketing, it will provide more options for the domestic vaccinated population and help meet the clinical needs in the field of herpes zoster prevention in China.

Based on the Summary Report and the information available as at the date of this announcement, the Study has been successfully implemented and completed in accordance with the study protocol, and REC610 demonstrated an overall favourable safety and immunogenicity profile in the Study.

Immediately following the completion of the Summary Report, the Company will proactively communicate with the National Medical Products Administration of the People's Republic of China (NMPA) and the Center for Drug Evaluation (CDE) to fully advance the product application and review process. The Company will make further disclosure regarding any material progress of REC610 in due course in accordance with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

RISK WARNING

Due to the high-tech, high-risk and high value-added characteristics of pharmaceutical products, significant risks and uncertainties exist in the research, development and commercialization process of pharmaceutical products. The acceptance of the new drug application for REC610 and its passing of the relevant on-site inspections do not guarantee that REC610 will ultimately obtain approval for marketing, and the Group may not successfully develop or market REC610.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, October 29, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive director, Dr. LIU Yong and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.